Variantyx News
20 articles
Variantyx Brings the First Combined Short- and Long-Read Whole Genome Sequencing Test to Market with Genomic Unity® 2.0
Variantyx Secures $36M Investment As Testing Demand And Market Share Continues To Increase
Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis
Variantyx Announces Additional Investment Enabling Rapid Expansion of Its Commercial Footprint
Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round
Variantyx nabs $41.1M for tech-backed genomic analysis
Variantyx, a startup focused on precision medicine in genomic testing, has raised $41.5 million in a C-2 funding round. The company offers whole genome sequencing and an analytics platform to interpret the data. The funding will be used to expand market reach and focus on precision oncology. Precision genomics is becoming more prominent in healthcare, with companies like SeqOne Genomics and Deep Genomics also securing significant funding. Variantyx aims to help clinicians gain insights into patients genetic makeup for personalized treatment recommendations. The company plans to share new disruptive products in the pipeline.
InvestmentExpand
Variantyx Expands Into Prenatal, Cancer Testing
Variantyx, a genetic testing company, is expanding its menu to include prenatal and pan-cancer testing in the US. The company has launched its Genomic Unity Prenatal Analysis test, which analyzes amniotic fluid and blood from both parents to provide a genomic analysis of the fetus. They are also developing a genomic profiling test for cancer that will analyze tumor and normal tissue. The new assays will expand Variantyxs existing clinical testing menu for hereditary disease. The company has already been servicing prominent healthcare systems in the US. Variantyx has raised $20 million in a Series C financing round and plans to bring more sequencing in-house. They have secured reimbursement from more than half of commercial payers and are planning to use long and short reads for sequencing in the future.
CustomersExpand
Variantyx Secures $20M in Funding for Whole Genome Sequencing Methodology, Advanced Testing Method that Diagnoses Genetic Disorders
Variantyx Launches Its WGS-Based Prenatal Test for High-Risk Pregnancies, Enters Women's Health Market
News: Variantyx Licenses IBM Technologies That Leverage AI for Somatic Analysis - Variantyx
Council Post: A Shorter Path To Genetic Testing Clarity
The article discusses the benefits of using whole genome sequencing (WGS) as a first-line approach in genetic testing for diagnosing diseases. It highlights the limitations of the traditional trial-and-error method and the potential of WGS to provide quicker and more accurate diagnoses. The adoption of WGS could significantly reduce the time and cost involved in genetic testing, benefiting patients and their families. However, the article also emphasizes the need for support and reimbursement from the health insurance industry to fully realize the potential of WGS-based testing. The impact on Variantyx, the company mentioned in the article, is growth-positive as it offers WGS-based testing services.
CustomersPartners
AMA Issues PLA Codes for Variantyx's Genomic Unity® Test Series
Variantyx Launches Its Whole Genome Sequencing (WGS)-Based In-Silico Panel Program at National Society of Genetic Counselors Annual Conference
Genomic Testing Firm Variantyx Receives $7M Investment from Pitango Venture Capital
Clinical genomic testing company Variantyx has received a $7 million investment from Pitango Venture Capital. The funding is part of Pitangos new Pitango HealthTech Fund. Variantyx provides clinical genomic testing for screening and rare disease diagnostics. They have integrated their testing pipeline with FDNAs Face2Gene phenotyping technology and have launched a program for free whole genome sequencing-based testing for rare-disease patients.
Investment
Variantyx Launches Its RareDx Program, Providing Clinical Whole Genome Testing to Enrolled Patients
http://www.frontlinegenomics.com/opinion/17197/exomes-transition-test/
Variantyx Launches Variantyx Unity™, The All-In-One Genomic Diagnostic Test
Variantyx and FDNA Announce Integration of their Applications to Facilitate Rare Disease Diagnosis
Startup Variantyx Sees Itself As 'Virtual Lab' for Diagnostic Decision Support
Diagnostic decision support company Variantyx is betting on the trend towards whole-genome sequencing. The company introduced its cloud-based Genomic Intelligence platform, which automates the NGS testing process and offers clinically actionable suggestions, at the American Society of Human Genetics annual conference. Variantyx sells its service by subscription and offers a pay-per-test option. As an introductory offer, the company is providing no-cost second opinions to practicing clinicians for undiagnosed cases. Variantyx has been self-funded by its founders to date. The company aims to help clinicians sort through genomic data and believes that whole-genome sequencing is the future.
CustomersPartners
Variantyx Launches Genomic Intelligence® Clinical Diagnostic Platform
